|
|
| (9 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{DiseaseDisorder infobox | | | {{status asthmaticus}} |
| Name = Status asthmaticus|
| |
| ICD10 = {{ICD10|J|46||j|40}} |
| |
| ICD9 = {{ICD9|493.01}}, {{ICD9|493.91}} |
| |
| }}
| |
| {{Asthma}}
| |
| '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | | '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' |
| | |
| {{CMG}}; {{AOEIC}} {{LG}} | | {{CMG}}; {{AOEIC}} {{LG}} |
|
| |
|
| ==[[Status asthmaticus overview|Overview]]== | | ==[[Status asthmaticus overview|Overview]]== |
|
| |
| ==[[Status asthmaticus historical perspective|Historical Perspective]]==
| |
|
| |
| ==[[Status asthmaticus classification|Classification]]==
| |
|
| |
|
| ==[[Status asthmaticus pathophysiology|Pathophysiology]]== | | ==[[Status asthmaticus pathophysiology|Pathophysiology]]== |
| Line 19: |
Line 11: |
| ==[[Status asthmaticus causes|Causes]]== | | ==[[Status asthmaticus causes|Causes]]== |
|
| |
|
| ==[[Status asthmaticus differential diagnosis|Differentiating Status asthmaticus from other Diseases]]== | | ==[[Status asthmaticus differential diagnosis|Differentiating Status Asthmaticus from other Diseases]]== |
|
| |
|
| ==[[Status asthmaticus epidemiology and demographics|Epidemiology and Demographics]]== | | ==[[Status asthmaticus epidemiology and demographics|Epidemiology and Demographics]]== |
|
| |
|
| ==[[Status asthmaticus risk factors|Risk Factors]]== | | ==[[Status asthmaticus risk factors|Risk Factors]]== |
|
| |
| ==[[Status asthmaticus screening|Screening]]==
| |
|
| |
|
| ==[[Status asthmaticus natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | | ==[[Status asthmaticus natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
| Line 31: |
Line 21: |
| ==Diagnosis== | | ==Diagnosis== |
|
| |
|
| [[Status asthmaticus diagnostic criteria|Diagnostic Criteria]] | [[Status asthmaticus history and symptoms|History and Symptoms]] | [[Status asthmaticus physical examination|Physical Examination]] | [[Status asthmaticus laboratory findings|Laboratory Findings]] | [[Status asthmaticus chest x ray|Chest X ray]] | [[Status asthmaticus CT|CT]] | [[Status asthmaticus MRI|MRI]] | [[Status asthmaticus other imaging findings|Other Imaging Findings]] | [[Status asthmaticus other diagnostic studies|Other Diagnostic Studies]]
| | [[Status asthmaticus history and symptoms|History and Symptoms]] | [[Status asthmaticus physical examination|Physical Examination]] | [[Status asthmaticus laboratory findings|Laboratory Findings]] | [[Status asthmaticus electrocardiogram|Electrocardiogram]] | [[Status asthmaticus chest x ray|Chest X ray]] | [[Status asthmaticus CT|CT]] | [[Status asthmaticus MRI|MRI]] | [[Status asthmaticus other imaging findings|Other Imaging Findings]] | [[Status asthmaticus other diagnostic studies|Other Diagnostic Studies]] |
|
| |
|
| ==Treatment== | | ==Treatment== |
|
| |
|
| [[Status asthmaticus medical therapy|Medical Therapy]] | [[Status asthmaticus surgery|Surgery]] | [[Status asthmaticus primary prevention|Primary Prevention]] | [[Status asthmaticus secondary prevention|Secondary Prevention]] | [[Status asthmaticus cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Status asthmaticus future or investigational therapies|Future or Investigational Therapies]] | | [[Status asthmaticus medical therapy|Medical Therapy]] | [[Status asthmaticus primary prevention|Primary Prevention]] | [[Status asthmaticus secondary prevention|Secondary Prevention]] | [[Status asthmaticus cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Status asthmaticus future or investigational therapies|Future or Investigational Therapies]] |
|
| |
|
| ==Case Studies== | | ==Case Studies== |
| [[Status asthmaticus case study one|Case #1]] | | [[Status asthmaticus case study one|Case #1]] |
|
| |
|
| |
|
| |
| ==Epidemiology==
| |
| Approximately 10% of the US population is affected by asthma and an increased prevalence of 60% is observed in all age groups, with status asthmaticus requiring the highest rates of hospitalization.<ref name="pmid18955910">Gorelick M, Scribano PV, Stevens MW, Schultz T, Shults J (2008) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18955910 Predicting need for hospitalization in acute pediatric asthma.] ''Pediatr Emerg Care'' 24 (11):735-44. [http://dx.doi.org/10.1097/PEC.0b013e31818c268f DOI:10.1097/PEC.0b013e31818c268f] PMID: [http://pubmed.gov/18955910 18955910]</ref>
| |
|
| |
| ==Predisposing factors==
| |
| *Increase use of [[bronchodilator]] despite resistance,
| |
| *Frequent exacerbations despite the use of [[corticosteroids]],
| |
| *Despite adhering to therapy, a [[Asthma pulmonary function test#Peak Expiratory Flow Rate|peak flow rate]] of less than 10% from baseline,
| |
| *Frequent hospitalization for acute attacks,
| |
| *History of [[syncope]] or [[seizure]] during an acute asthmatic attack,
| |
| *[[Asthma laboratory tests#Pulse Oximetry|Oxygen saturation]] lower than 92% despite supplemental oxygen,
| |
| *Airway obstruction is significantly reduced, resulting in severe impairment of air motion that leads to a '''silent chest''' with the absence of [[wheeze]] suggestive of an [[respiratory failure|imminent respiratory arrest]].
| |
|
| |
| ==Diagnosis==
| |
| ===History and Symptoms===
| |
| *[[dyspnea|Rapidly progressive dyspnea]]
| |
| *[[cough|Non-productive cough]]
| |
| *[[sweating|Profuse sweating]]
| |
| *[[Cyanosis|Central cyanosis]]
| |
| *[[Loss of consciousness]] and/or [[seizure]] secondary to [[hypoxia|severe hypoxia]] may be observed
| |
| *Inability to speak more than one or two words may be observed with severe airway obstruction
| |
|
| |
| ===Physical Examination===
| |
| ====Vital Signs====
| |
| *[[Tachypnea|Increased respiratory rate]] greater than 30 cycles per minute
| |
| *[[Tachycardia|Increased heart rate]]
| |
| *[[Pulsus paradoxus]] (fall in [[Systolic blood pressure|SBP]] greater than 20-40 mmHg during inspiration)
| |
|
| |
| ====General Physical Examination====
| |
| *Sit upright with arms extended to support the upper chest ('''tripod position''') that assists the use of accessory muscles of respiration
| |
| *[[Asthma pulmonary function test#Peak Expiratory Flow Rate|Peak flow rate]] measurement is a simple bedside method to assess the severity of airway obstruction. A '''red zone''' indicates less than 50% of the usual or normal peak flow reading signifying a severe airway obstruction.
| |
|
| |
| ====Respiratory Examination====
| |
| =====Inspection=====
| |
| *Use of accessory muscles of respiration such as [[sternocleidomastoid]], [[scalene]] and intercostal muscles, correlates with the disease severity
| |
| *Intercostal retractions
| |
| *Paradoxical thoraco-abdominal breathing
| |
|
| |
| =====Auscultation=====
| |
| *High-pitch prolong polyphonic expiratory [[wheeze]]
| |
| *Bilateral crackles
| |
| *Air entry may or may not be reduced depending on the disease severity
| |
| *Absence of [[wheeze]] and [[breath sounds]] secondary to severe airway obstruction may represent a '''silent chest''' which is an ominous sign of imminent [[respiratory failure]].
| |
|
| |
| ====Cardiovascular Examination====
| |
| Progressive untreated airway obstruction and increased work of breathing eventually leads to worsening [[hypoxemia]], [[hypercarbia]] and increased [[air trapping]] with compromised [[stroke volume]] that results in [[bradycardia]], [[hypotension]], [[hypoventilation]] and subsequent [[cardiorespiratory arrest]].
| |
|
| |
| ====Neurological Examination====
| |
| *Level of consciousness ranges from lethargy, agitation to even [[loss of consciousness]] or [[seizure]], secondary to severe airway obstruction, [[hypoxia]] and carbon-di-oxide retention.
| |
| *Unable to speak in full sentences
| |
|
| |
| ===Laboratory Tests===
| |
| *Measurement of oxygen saturation by [[Asthma laboratory tests#Pulse Oximetry|pulse oximetry]] may be useful to identify patients with acute severe asthma who may rapidly progress to [[respiratory failure]] and thereby require more intensive therapy.<ref name="pmid1121560">Overall JE (1975) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1121560 Rating session. Video taped interviews and BPRS ratings.] ''Psychopharmacol Bull'' 11 (1):15. PMID: [http://pubmed.gov/1121560 1121560]</ref>
| |
|
| |
| *[[Arterial blood gas]] may reveal [[respiratory alkalosis]] that is consistent with the [[hypoxemia]] and/or [[hypercarbia]] secondary to significant [[hypoventilation]].
| |
|
| |
| *[[Asthma laboratory tests|CBC count]] may demonstrate an increase in [[white blood cell|peripheral WBCs]] secondary to the use of [[steroids]] and [[Bronchodilators|β-agonists]].
| |
|
| |
| ===Pulmonary Function Test===
| |
| [[Spirometry#Explanation of common test values in FVC tests|FEV1]] '''lower than 60% predicted''' is strongly suggestive of severe airway obstruction.
| |
|
| |
| ===ECG===
| |
| The presence of [[supraventricular tachycardia]] on ECG should raise a suspicion of [[Bronchodilator#Theophylline|theophylline toxicity]].
| |
|
| |
| ===Imaging Modalities===
| |
| [[Asthma CT|High-resolution CT]] may reveal several structural changes related to small-airway disease including [[Bronchiectasis|cylindrical bronchiectasis]], bronchial wall thickening, and [[air trapping]].<ref name="pmid1094668">Robards VL, Lubin EN, Medlock TR (1975) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1094668 Renal transplantation and placement of ileal stoma.] ''Urology'' 5 (6):787-9. PMID: [http://pubmed.gov/1094668 1094668]</ref>
| |
|
| |
| ==Stating based on Arterial Blood Gas Analysis==
| |
| ====Stage 1====
| |
| *[[Hyperventilation]] with normal PO<sub>2</sub>
| |
| *No [[hypoxemia]]
| |
| *Patients may benefit from nebulized [[ipratropium]] used adjunctive to [[Bronchodilator|β2-agonist]] therapy
| |
|
| |
| ====Stage 2====
| |
| *[[Hyperventilation]] with [[hypoxemia]] (low PO<sub>2</sub> and PCO<sub>2</sub>)
| |
| *Patients may require [[corticosteroids]] in addition to [[bronchodilator]] therapy
| |
|
| |
| ====Stage 3====
| |
| *[[CO2 retention]] due to respiratory muscle fatigue
| |
| *Markedly elevated PCO2 levels are an indicator for mechanical ventilation
| |
| *Aggressive [[Bronchodilator|β2-agonist]] therapy along with parenteral [[steroids]] and/or [[Bronchodilator#Theophylline|theophylline]] is indicated
| |
|
| |
| ====Stage 4====
| |
| *Severe [[hypoxia]] with markedly elevated PCO<sub>2</sub>
| |
| *[[FEV1]] lower than 20% predicted is suggestive of an impending [[respiratory failure|respiratory arrest]] that may require [[intubation]] and [[mechanical ventilation]]
| |
| *Metered-dose inhalation of [[Bronchodilator|β2-agonist]] and [[Bronchodilator#Anticholinergics|anticholinergics]] are recommended. Administration of parenteral [[steroids]] and/or [[Bronchodilator#Theophylline|theophylline]] has also shown to be beneficial.
| |
|
| |
| ==Treatment==
| |
| *Initial severity assessment is evaluated using [[Asthma laboratory tests#Arterial Blood Gas|arterial blood gas]] and [[Asthma pulmonary function test|pulmonary function test]] and aggressive therapy is initiated to prevent progression to [[respiratory failure]]
| |
|
| |
| *'''Supplemental [[oxygen]]''' via nasal canula or [[face mask]] is recommended to alleviate severe [[hypoxia]]. Oxygen saturation is maintained above 92% and is monitored using [[Asthma laboratory tests#Pulse Oximetry|pulse Oximetry]]
| |
|
| |
| *Mainstay drugs for the management include '''nebulized [[Bronchodilator|β2-agonists]]''' such as [[albuterol]], [[salbutamol]] or [[terbutaline]], '''parenteral [[steroids]]''' such as [[hydrocortisone]] or [[prednisolone]] and '''[[Bronchodilator#Theophylline|theophylline]]'''
| |
|
| |
| *[[Bronchodilator#Anticholinergics|Anti-cholinergics]] such as '''[[ipratropium bromide]]''' may be indicated in patients who are unable to tolerate inhaled [[Bronchodilator|β2-agonists]].
| |
|
| |
| *In patients non-responsive to nebulized [[bronchodilator]], '''IV-[[aminophylline]]''' or '''oral-[[Leukotriene antagonist|leukotriene inhibitor]]''' may be used.<ref name="pmid1934839">Press S, Lipkind RS (1991) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1934839 A treatment protocol of the acute asthma patient in a pediatric emergency department.] ''Clin Pediatr (Phila)'' 30 (10):573-7. PMID: [http://pubmed.gov/1934839 1934839]</ref>
| |
|
| |
| *'''Helium with oxygen mixture''' has shown to reduce airway resistance and thereby reduce the work of breathing and also improve [[bronchodilator]] efficacy.
| |
|
| |
| *Use of [[Magnesium sulfide|magnesium sulphate]] administered either IV or nebulized in addition to [[Bronchodilator|β2-agonists]] remains controversial.<ref name="pmid11097697">Scarfone RJ, Loiselle JM, Joffe MD, Mull CC, Stiller S, Thompson K et al. (2000) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11097697 A randomized trial of magnesium in the emergency department treatment of children with asthma.] ''Ann Emerg Med'' 36 (6):572-8. [http://dx.doi.org/10.1067/mem.2000.111060 DOI:10.1067/mem.2000.111060] PMID: [http://pubmed.gov/11097697 11097697]</ref><ref name="pmid12023699">Bessmertny O, DiGregorio RV, Cohen H, Becker E, Looney D, Golden J et al. (2002) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12023699 A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults.] ''Ann Emerg Med'' 39 (6):585-91. PMID: [http://pubmed.gov/12023699 12023699]</ref><ref name="pmid12501154">Glover ML, Machado C, Totapally BR (2002) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12501154 Magnesium sulfate administered via continuous intravenous infusion in pediatric patients with refractory wheezing.] ''J Crit Care'' 17 (4):255-8. [http://dx.doi.org/10.1053/jcrc.2002.36759 DOI:10.1053/jcrc.2002.36759] PMID: [http://pubmed.gov/12501154 12501154]</ref><ref name="pmid15846687">Blitz M, Blitz S, Beasely R, Diner BM, Hughes R, Knopp JA et al. (2005) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15846687 Inhaled magnesium sulfate in the treatment of acute asthma.] ''Cochrane Database Syst Rev'' (2):CD003898. [http://dx.doi.org/10.1002/14651858.CD003898.pub2 DOI:10.1002/14651858.CD003898.pub2] PMID: [http://pubmed.gov/15846687 15846687]</ref>
| |
|
| |
| *'''Non-invasive ventilation''' using [[Positive airway pressure|C-PAP]] or tight-fitting [[Medical ventilator|face mask]] may be used to reduce the work of breathing without intubation.
| |
|
| |
| *'''[[Tracheal intubation|Endotracheal intubation]]''' and '''[[mechanical ventilation]]''' should be used with caution in asthmatics who are non-responsive to medical therapy or non-invasive methods of ventilation, due to the substantial risk of [[barotrauma]]. Common indications include impending [[respiratory failure|respiratory arrest]], [[hypoxia|severe hypoxia]] non-responsive to supplemental [[oxygen]], [[CO2 retention]] with PaCO<sub>2</sub> greater than 50 mmHg, [[acidosis]] and/or altered mental status.
| |
|
| |
| ==Complications==
| |
| *[[Pneumothorax]] as a complication of [[mechanical ventilation]]
| |
| *Intubation increases the risk of super-imposed infection
| |
|
| |
| ==Prevention==
| |
| *Compliant to medications
| |
| *Avoid [[Asthma risk factors|triggering factors]]
| |
|
| |
| ==References==
| |
| {{reflist|2}}
| |
|
| |
|
| [[Category:Asthma]] | | [[Category:Asthma]] |
|
| |
| [[Category:Disease]] | | [[Category:Disease]] |
| [[Category:Pulmonology]] | | [[Category:Pulmonology]] |
|
| |
| [[Category:Emergency medicine]] | | [[Category:Emergency medicine]] |
| [[Category:Intensive care medicine]] | | [[Category:Intensive care medicine]] |
|
| |
| [[Category:Up-To-Date]]
| |
| [[Category:Up-To-Date pulmonology]]
| |
|
| |
|
| {{WikiDoc Help Menu}} | | {{WikiDoc Help Menu}} |
| {{WikiDoc Sources}} | | {{WikiDoc Sources}} |